MCET Recent activities 08/26/2014 07:22:40 $MCET Time to

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
MCET Recent activities 08/26/2014 07:22:40 $MCET
Time to get paid years of waiting FINALLY.

Over 1 billion shares traded around March. Check links below for
Partners,Therapeutic Pipeline and Published Patents.



Thursday, 03/20/14 09:50:05 AM

Re: None
Post # of 37818
This is huge MCT-485 has demonstrated in in vitro models the ability to kill transformed liver cancer cells while not harming normal, non-transformed liver cells. "MCT-485 addresses the need to directly target liver cancer cells and not normal liver cells", said W. Gerald Newmin, Chairman and Chief Executive Officer. MCT-485 is currently being evaluated in animal models of hepatocellular carcinoma. MultiCell also plans to study MCT-485 in relevant in vitro and animal models for other major cancers.

finance.yahoo.com/news/multicell-technologies-files-u-international-123900101.html

http://www.multicelltech.com/therapeutic-pipe...-pipeline/

http://www.multicelltech.com/therapeutic-pipe...d-patents/
http://www.multicelltech.com/about-us/partners/


MCET-MultiCell-5-10X Bagger from here. Market cap of a few million is so discounted and severely undervalued. Actc-same shares out and at .07+
Expect to see some major Partnership/Collaborations and Licensing deals in the near future. Market cap is extremely low and discounted here considering their stage and recent developments. Expecting the next PR involving a major Pharma!!!



MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer

WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity.

In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the

MCET Stock Message Board http://investorshangout.com/Multicell-Techs-Inc-MCET-64069/

confidential treatment order? I bet they already are!
For anyone new here just keep a few things in mind. MultiCell hardly ever puts out press releases and when they do it's the real deal. Multicell has spent years on research & development which they did have to dilute the O/S to keep the lights on which is understandable in the R&D space.

All of this scientific research for curing cancer, hepatitis, etc is finally showing us the light at the end of the tunnel for shareholders. MultiCell has long relationships with Pfizer, Corning, and Amarin which my guess is one of them will make a buyout offer in the near-term. So the current share structure doesn't concern me, although it's not great. The price to cure cancer/hepatitis is priceless in my opinion so sit back relax as we may be sitting on the golden ticket here.

Just my opinion and good luck to all.
I'd say a larger Pharma partnership/ licensing deal first. Once this happens people will be chasing this up in cents.
Matter of time imo
Are you kidding me- market cap at these prices it's absolutely peanuts and nothing which upside of 10-20X++
This patent win will lead the doors to possible partnership, licensing deals and much more. All it'll take is 1 large Pharma involving any of these and this'll explode!!!
Patience and we shall see some huge returns from these discounted levels
I read patent approval and it seems to me it is working . Even found exact place where mice developed immunity agains cancer . I mentioned it in first post .
http://www.shortanalytics.com/getshortchart.php?tsymbol=mcet
503 mill long -248 mill short shares yesterday .
Yep exactly! 3.7BN at .0011 is no biggie. Tiresome these scare tactics about O/S at these trip zero prices.
Yep Odessa..huge!
MCET - honestly... The patent approval makes us more poised for a green day tomorrow IMHO... I was just pointing out what i saw in the charts historically.

I grabbed some .001s today too.

Let's see what happens.


ehhh. I'm gonna say that basing tomorrow's move on "history repeating itself" is something you gotta watch out for especially people that decided to short this today, which based on the short volume looks to be over 30%. I'm sure that all the shorts are hoping history will repeat itself, but what if history doesn't repeat itself and we get a massive short covering tomorrow? It could happen and in fact I hope it does. GLTA
You think Chrion? I added a few at .001 and bidding for more at .0009 ~ I think we see a move to the .0016-.0018 range IMO
Now that they have a US Patent, can we expect production deal NEWS soon ?
Get in tomorrow before it bursts UP
Nice run today, hope you all got out??
Nice day here. More coming?
Open at .0014 tomorrow
+>>>MCET: Tomorrow's Guess - Historical Pattern<<<+

-Not Saying this is what will happen tomorrow...
-So Please Refrain From Throwing Rock's in my eye
-Good Job to those that paid attention to my alert this morning...
[Click HERE or HERE or HERE]



Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 35

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Morrison Tests Abu Dhabi as Its Next Capital Hub

Updated Category News Views 60

Abu Dhabi keeps collecting infrastructure managers the way a strong port collects ships: because the money, the policy ambition, and the projects are all converging there. Morrison’s decision to establish an office in ADGM is not some chest-thumping headline about instant deal flow. It is a practical move by a firm with nearly four decades behind it and more than US$35...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 96

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 46

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 33

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading

Top 5 Most Recently Viewed Articles

Winter Weather in California: Safeguarding Your Home's Integrity

Updated Category News Views 107

California's Winter Weather: A Wake-Up Call for Homeowners As California braces for a challenging winter season characterized by heavy rains and potential flash floods, homeowners must recognize the structural risks to their properties. Alpha Structural, Inc. emphasizes the importance of proactive measures to safeguard homes against these weather-related threats....

Continue Reading
WELL Health Advances with Expanding Clinics and Public Sector Growth

Updated Category News Views 322

WELL Health's Growing Clinics and Services WELL Health Technologies Corp. is making significant strides in the Canadian healthcare landscape. Recently, the company reported expanding its network by adding 11 new clinics, a move that reflects its commitment to enhancing healthcare access and quality across the country. This new addition comprises 9 clinics acquired and 2...

Continue Reading
Growth Surge in Australia's Construction Market Expected Until 2029

Updated Category News Views 162

Overview of Australia's Construction Market Growth The Australian construction landscape is poised for a significant transformation, anticipating a remarkable growth spurt of USD 42.1 billion from 2025 to 2029. As urban migration steadily rises, the demand for diverse construction projects, encompassing both residential and commercial sectors, is increasingly pronounced....

Continue Reading
Market Insights: Indonesian Stocks Encounter Declines Today

Updated Category News Views 251

Market Overview: Indonesian Stocks on the Decline Today’s trading session in Indonesia witnessed a downward trend, as the stock market closed with losses influenced primarily by the Financials, Agriculture, and Basic Industry sectors. This decline reflects broader market sentiments and economic factors affecting investor decisions. IDX Composite Index Performance The...

Continue Reading
Dowlais Group plc and Recent Share Dealings Analysis

Updated Category News Views 193

Understanding Recent Dealings In Dowlais Group Plc Investors have been keenly observing the movements and transactions of Dowlais Group Plc, particularly as the company continues to navigate the complexities of the market. A significant reporting came in the form of disclosures related to share purchases and sales, which are vital for understanding the company's financial...

Continue Reading